Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
31.82
-0.57 (-1.76%)
Apr 29, 2026, 11:43 AM EDT - Market open
Viking Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -359.64 | -109.96 | -85.9 | -68.87 | -54.99 | |
| Depreciation & Amortization | 0.43 | 0.35 | 0.29 | 0.29 | 0.3 | |
| Other Amortization | 0.06 | 0.09 | 0.09 | 0.06 | 0.02 | |
| Loss (Gain) From Sale of Investments | -9.34 | -17.38 | -8.2 | 1.22 | 3.91 | |
| Stock-Based Compensation | 40.82 | 29.71 | 16.75 | 8.67 | 6.1 | |
| Other Operating Activities | 0.01 | 0.04 | 0.04 | 0.04 | 0.01 | |
| Change in Accounts Payable | 43.44 | 2.3 | -1.02 | 7.09 | -2.54 | |
| Change in Other Net Operating Assets | 5.54 | 7.06 | 4.57 | 3.1 | -0.38 | |
| Operating Cash Flow | -278.69 | -87.79 | -73.38 | -48.4 | -47.59 | |
| Investment in Securities | 341.39 | -553.37 | -179.09 | 54.75 | 37.96 | |
| Investing Cash Flow | 341.39 | -553.37 | -179.09 | 54.75 | 37.96 | |
| Issuance of Common Stock | 76.44 | 654.57 | 278.5 | 12.51 | 7.63 | |
| Repurchase of Common Stock | - | -42.1 | -7.12 | -8.33 | -0.71 | |
| Other Financing Activities | - | - | - | -0.02 | -0.05 | |
| Financing Cash Flow | 76.44 | 612.46 | 271.38 | 4.16 | 6.88 | |
| Foreign Exchange Rate Adjustments | -0.01 | -0.15 | -0.03 | -0.26 | - | |
| Net Cash Flow | 139.13 | -28.84 | 18.88 | 10.26 | -2.75 | |
| Levered Free Cash Flow | -160.22 | -55.58 | -42.36 | -25.22 | -32.16 | |
| Unlevered Free Cash Flow | -160.24 | -55.61 | -42.4 | -25.24 | -32.16 | |
| Change in Working Capital | 48.98 | 9.36 | 3.55 | 10.19 | -2.93 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.